Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which completed phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. Scancell Holdings plc has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; and licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1. The company was founded in 1997 and is based in Oxford, the United Kingdom.